Case report: Lyell leverages Werum PAS-X MES as a Service for clinical phase production
The US-based cell therapy biotech Lyell Immunopharma has successfully taken Werum PAS-X MES as a Service into operation at their GMP production site in Bothell, WA to produce autologous T cell cancer therapies.
![Cover_Koerber_sof_0068_Lyell_CS_EN Cover_Koerber_sof_0068_Lyell_CS_EN](https://service.koerber-pharma.com/hs-fs/hubfs/K%C3%B6rber%20Pharma/Software/Cover/Cover_Koerber_sof_0068_Lyell_CS_EN.jpg?width=350&height=495&name=Cover_Koerber_sof_0068_Lyell_CS_EN.jpg)